ישראל - עברית - Ministry of Health

taro international ltd, israel - esomeprazole as sodium - אבקה להמסה להזרקה\אינפוזיה - esomeprazole as sodium 40 mg/dose - esomeprazole - esomeprazole - nexium iv is indicated for gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate.prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.

ישראל - עברית - Ministry of Health

taro international ltd, israel - latanoprost; timolol as maleate - טיפות עיניים - timolol as maleate 5.0 mg/ml; latanoprost 0.05 mg/ml - timolol

ישראל - עברית - Ministry of Health

taro international ltd, israel - bromfenac as sodium sesquihydrate - תמיסה לעין - bromfenac as sodium sesquihydrate 0.075 %w/w - bromfenac

ישראל - עברית - Ministry of Health

taro international ltd, israel - sildenafil as citrate - תרחיף - sildenafil as citrate 25 mg / 1 ml - sildenafil

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - chlorhexidine gluconate - תמיסה - chlorhexidine gluconate 0.2 %w/v - chlorhexidine - chlorhexidine - 1. as an aid to maintaining oral hygiene.2. as an aid in the treatment and prevention of gingivitis.3. inhibition of formation of dental plaque.4. for use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush).5. for use in a post- periodontal surgery or treatment regimen to promote gingival healing.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 3 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 4 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.